Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01494922 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001
A Phase 2 study of Reduction in Severity of Skin Scarring, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 4
- Study locations
NCT01494922: Completed Phase 2 study of Reduction in Severity of Skin Scarring, sponsored by Pfizer.
NCT01494922 is a Phase 2 study of Reduction in Severity of Skin Scarring that has completed, run by Pfizer. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01494922, a Phase 2 study of Reduction in Severity of Skin Scarring, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to provide subjects who participated in prior studies of EXC 001 the opportunity to have their hypertrophic scars surgically revised and treated with EXC 001.
Primary Outcome
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included SAEs and all non-SAEs that occurred during the study.
Conditions Studied
Interventions
- DRUG EXC 001 (currently called PF-06473871)
Study Locations (4)
Oregon
- Jewell Plastic Surgery Center - Eugene
- Connall Consmetic Surgery - Tualatin
Florida
- Altus Research - Lake Worth
Illinois
- Northwestern University,Division of Plastic Surgery - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-12-08 |
| Est. Completion | 2013-09-10 |
| Phase | Phase 2 |
What the finished NCT01494922 record still lists
NCT01494922 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Reduction in Severity of Skin Scarring appearing as the primary indexed condition, and to 1 intervention - of which EXC 001 (currently called PF-06473871) is the first listed.
NCT01494922 reports a single indexed study location in Oregon, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT01494922 about?
NCT01494922 is a clinical study titled "Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001". The purpose of this study is to provide subjects who participated in prior studies of EXC 001 the opportunity to have their hypertrophic scars surgically revised and treated with EXC 001.
What is the current status of trial NCT01494922?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2011-12-08. Estimated completion is 2013-09-10.
What conditions does trial NCT01494922 study?
This clinical trial studies the following conditions: Reduction in Severity of Skin Scarring.
What interventions are being tested in trial NCT01494922?
The interventions under investigation include: EXC 001 (currently called PF-06473871) (DRUG).
Who is sponsoring clinical trial NCT01494922?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01494922 being conducted?
This trial has 4 study locations across Florida, Illinois, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01494922's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy